Equities researchers at Wolfe Research started coverage on shares of Medpace (NASDAQ:MEDP) in a research note issued to investors on Tuesday, April 2nd, The Fly reports. The firm set an “outperform” rating on the stock.
A number of other research analysts have also issued reports on MEDP. ValuEngine lowered Medpace from a “buy” rating to a “hold” rating in a research report on Thursday, December 6th. BidaskClub lowered Medpace from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, December 18th. Zacks Investment Research lowered Medpace from a “buy” rating to a “hold” rating in a research report on Wednesday, January 9th. Finally, TheStreet lowered Medpace from a “b” rating to a “c” rating in a research report on Friday, March 22nd. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. Medpace currently has a consensus rating of “Buy” and a consensus price target of $55.33.
Shares of NASDAQ MEDP traded up $0.86 during trading on Tuesday, reaching $58.71. The stock had a trading volume of 234,790 shares, compared to its average volume of 642,650. Medpace has a one year low of $35.00 and a one year high of $71.66. The company has a current ratio of 0.69, a quick ratio of 0.69 and a debt-to-equity ratio of 0.18. The company has a market capitalization of $2.10 billion, a price-to-earnings ratio of 22.67, a price-to-earnings-growth ratio of 1.81 and a beta of 1.62.
In other news, General Counsel Stephen P. Ewald sold 7,946 shares of the business’s stock in a transaction on Friday, March 29th. The stock was sold at an average price of $57.95, for a total transaction of $460,470.70. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO August J. Troendle sold 4,221 shares of the business’s stock in a transaction on Monday, January 28th. The stock was sold at an average price of $61.04, for a total value of $257,649.84. Following the sale, the chief executive officer now directly owns 603,702 shares in the company, valued at $36,849,970.08. The disclosure for this sale can be found here. In the last 90 days, insiders sold 566,049 shares of company stock valued at $36,097,951. Insiders own 24.20% of the company’s stock.
A number of large investors have recently bought and sold shares of the stock. LS Investment Advisors LLC acquired a new position in Medpace in the 4th quarter worth about $46,000. SHANDA ASSET MANAGEMENT HOLDINGS Ltd bought a new stake in shares of Medpace during the 4th quarter worth about $87,000. State of Alaska Department of Revenue bought a new stake in shares of Medpace during the 4th quarter worth about $92,000. NumerixS Investment Technologies Inc bought a new stake in shares of Medpace during the 4th quarter worth about $119,000. Finally, We Are One Seven LLC bought a new stake in shares of Medpace during the 4th quarter worth about $130,000. 82.88% of the stock is currently owned by hedge funds and other institutional investors.
Medpace Company Profile
Medpace Holdings, Inc, a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas.
Further Reading: What causes a recession?
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.